Figure 3. Precision therapies for fatty liver disease.

Microbiome studies might identify new pathways and factors that contribute to progression of fatty liver diseases; these might be used to assign patients to subgroups and identify those associated with specific alterations to the gut microbiota. Integration of this knowledge into diagnostic analyses might increase diagnostic and prognostic accuracy, and lead to personalized microbiota-based therapeutics. These approaches could increase therapeutic efficacy and reduce treatment-associated side effects, compared with standard approaches.